H Lundbeck A/S (HLUN-B) - Net Assets

Latest as of December 2025: Dkr24.90 Billion DKK ≈ $3.90 Billion USD

Based on the latest financial reports, H Lundbeck A/S (HLUN-B) has net assets worth Dkr24.90 Billion DKK (≈ $3.90 Billion USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Dkr54.01 Billion ≈ $8.45 Billion USD) and total liabilities (Dkr29.11 Billion ≈ $4.55 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets Dkr24.90 Billion
% of Total Assets 46.11%
Annual Growth Rate 5.66%
5-Year Change 36.24%
10-Year Change 156.89%
Growth Volatility 12.9

H Lundbeck A/S - Net Assets Trend (2004–2025)

This chart illustrates how H Lundbeck A/S's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for H Lundbeck A/S (2004–2025)

The table below shows the annual net assets of H Lundbeck A/S from 2004 to 2025.

Year Net Assets Change
2025-12-31 Dkr24.90 Billion
≈ $3.90 Billion
-0.43%
2024-12-31 Dkr25.01 Billion
≈ $3.91 Billion
+13.45%
2023-12-31 Dkr22.05 Billion
≈ $3.45 Billion
+6.09%
2022-12-31 Dkr20.78 Billion
≈ $3.25 Billion
+13.68%
2021-12-31 Dkr18.28 Billion
≈ $2.86 Billion
+7.69%
2020-12-31 Dkr16.97 Billion
≈ $2.66 Billion
+16.62%
2019-12-31 Dkr14.55 Billion
≈ $2.28 Billion
+2.13%
2018-12-31 Dkr14.25 Billion
≈ $2.23 Billion
+16.99%
2017-12-31 Dkr12.18 Billion
≈ $1.91 Billion
+25.66%
2016-12-31 Dkr9.69 Billion
≈ $1.52 Billion
+10.35%
2015-12-31 Dkr8.79 Billion
≈ $1.37 Billion
-35.05%
2014-12-31 Dkr13.53 Billion
≈ $2.12 Billion
+0.33%
2013-12-31 Dkr13.48 Billion
≈ $2.11 Billion
+2.14%
2012-12-31 Dkr13.20 Billion
≈ $2.06 Billion
+3.30%
2011-12-31 Dkr12.78 Billion
≈ $2.00 Billion
+14.87%
2010-12-31 Dkr11.12 Billion
≈ $1.74 Billion
+26.34%
2009-12-31 Dkr8.80 Billion
≈ $1.38 Billion
+15.95%
2008-12-31 Dkr7.59 Billion
≈ $1.19 Billion
+5.66%
2007-12-31 Dkr7.18 Billion
≈ $1.12 Billion
+6.21%
2006-12-31 Dkr6.76 Billion
≈ $1.06 Billion
-9.70%
2005-12-31 Dkr7.49 Billion
≈ $1.17 Billion
-4.43%
2004-12-31 Dkr7.84 Billion
≈ $1.23 Billion
--

Equity Component Analysis

This analysis shows how different components contribute to H Lundbeck A/S's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have grown by 268.9% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2025)

Component Amount Percentage
Retained Earnings Dkr24.61 Billion 98.84%
Common Stock Dkr996.00 Million 4.00%
Other Comprehensive Income Dkr-706.00 Million -2.83%
Total Equity Dkr24.90 Billion 100.00%

H Lundbeck A/S Competitors by Market Cap

The table below lists competitors of H Lundbeck A/S ranked by their market capitalization.

Equity Growth Attribution

This analysis shows how different factors contributed to changes in H Lundbeck A/S's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2024 to 2025, total equity changed from 25,010,000,000 to 24,903,000,000, a change of -107,000,000 (-0.4%).
  • Net income of 3,192,000,000 contributed positively to equity growth.
  • Dividend payments of 943,000,000 reduced retained earnings.
  • Share repurchases of 20,000,000 reduced equity.
  • Other comprehensive income decreased equity by 2,386,000,000.

Equity Change Factors (2024 to 2025)

Factor Impact Contribution
Net Income Dkr3.19 Billion +12.82%
Dividends Paid Dkr943.00 Million -3.79%
Share Repurchases Dkr20.00 Million -0.08%
Other Comprehensive Income Dkr-2.39 Billion -9.58%
Other Changes Dkr50.00 Million +0.2%
Total Change Dkr- -0.43%

Book Value vs Market Value Analysis

This analysis compares H Lundbeck A/S's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 1.76x
  • The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
  • The price-to-book ratio has decreased from 6.49x to 1.76x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2004-12-31 Dkr6.82 Dkr44.30 x
2005-12-31 Dkr6.66 Dkr44.30 x
2006-12-31 Dkr6.41 Dkr44.30 x
2007-12-31 Dkr7.01 Dkr44.30 x
2008-12-31 Dkr7.71 Dkr44.30 x
2009-12-31 Dkr8.98 Dkr44.30 x
2010-12-31 Dkr11.34 Dkr44.30 x
2011-12-31 Dkr13.03 Dkr44.30 x
2012-12-31 Dkr13.46 Dkr44.30 x
2013-12-31 Dkr13.74 Dkr44.30 x
2014-12-31 Dkr13.77 Dkr44.30 x
2015-12-31 Dkr8.93 Dkr44.30 x
2016-12-31 Dkr9.82 Dkr44.30 x
2017-12-31 Dkr12.32 Dkr44.30 x
2018-12-31 Dkr14.34 Dkr44.30 x
2019-12-31 Dkr14.65 Dkr44.30 x
2020-12-31 Dkr17.08 Dkr44.30 x
2021-12-31 Dkr18.40 Dkr44.30 x
2022-12-31 Dkr20.93 Dkr44.30 x
2023-12-31 Dkr22.22 Dkr44.30 x
2024-12-31 Dkr25.23 Dkr44.30 x
2025-12-31 Dkr25.10 Dkr44.30 x

Capital Efficiency Dashboard

This dashboard shows how efficiently H Lundbeck A/S utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 12.82%
  • The company shows good efficiency in utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 13.11%
  • • Asset Turnover: 0.45x
  • • Equity Multiplier: 2.17x
  • Recent ROE (12.82%) is below the historical average (14.93%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2004 21.79% 17.56% 0.85x 1.47x Dkr924.66 Million
2005 39.02% 32.23% 0.78x 1.55x Dkr2.17 Billion
2006 31.91% 23.41% 0.79x 1.72x Dkr1.48 Billion
2007 46.67% 30.53% 0.89x 1.72x Dkr2.64 Billion
2008 36.04% 24.25% 0.89x 1.66x Dkr1.98 Billion
2009 22.80% 14.60% 0.80x 1.95x Dkr1.13 Billion
2010 22.17% 16.70% 0.82x 1.62x Dkr1.35 Billion
2011 17.86% 14.26% 0.78x 1.61x Dkr1.00 Billion
2012 8.39% 7.48% 0.69x 1.63x Dkr-212.80 Million
2013 6.34% 5.60% 0.65x 1.75x Dkr-493.10 Million
2014 -1.13% -1.14% 0.53x 1.90x Dkr-1.51 Billion
2015 -64.82% -39.02% 0.68x 2.43x Dkr-6.57 Billion
2016 12.49% 7.75% 0.77x 2.08x Dkr241.60 Million
2017 21.54% 15.23% 0.87x 1.62x Dkr1.41 Billion
2018 27.42% 21.86% 0.78x 1.61x Dkr2.48 Billion
2019 18.32% 15.36% 0.49x 2.46x Dkr1.21 Billion
2020 9.31% 8.95% 0.49x 2.12x Dkr-116.30 Million
2021 7.21% 8.09% 0.47x 1.90x Dkr-509.90 Million
2022 9.22% 10.50% 0.49x 1.80x Dkr-161.90 Million
2023 10.39% 11.50% 0.53x 1.70x Dkr85.50 Million
2024 12.57% 14.28% 0.39x 2.28x Dkr642.00 Million
2025 12.82% 13.11% 0.45x 2.17x Dkr701.70 Million

Industry Comparison

This section compares H Lundbeck A/S's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

  • Industry: Drug Manufacturers - Specialty & Generic
  • Average net assets among peers: $6,398,236,094
  • Average return on equity (ROE) among peers: 0.93%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
H Lundbeck A/S (HLUN-B) Dkr24.90 Billion 21.79% 1.17x $5.50 Billion
H Lundbeck A/S (HLUN-A) $12.78 Billion 17.86% 0.61x $1.11 Billion
Stenocare AS (STENO) $20.47 Million -16.00% 0.06x $7.27 Million

About H Lundbeck A/S

CO:HLUN-B Denmark Drug Manufacturers - Specialty & Generic
Market Cap
$5.50 Billion
Dkr35.14 Billion DKK
Market Cap Rank
#3356 Global
#21 in Denmark
Share Price
Dkr44.30
Change (1 day)
+2.50%
52-Week Range
Dkr29.64 - Dkr47.34
All Time High
Dkr90.49
About

H. Lundbeck A/S engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company offers Abilify Maintena/ Abilify Asimtufii for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Rexulti/Rxulti to treat maj… Read more